Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma
Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 mAb, in combination with cetuximab, an anti-EGFR mAb, in sqNSCLC HMBD-001 used as monotherapy and in combination with cetuximab has been shown to effectively inhibit tumor growth across various preclinical squamous cell carcinoma models SAN FRANCISCO, … Read more